| Bioactivity | ALK/HDAC-IN-1 is a dual inhibitor for ALK and HADC6, with IC50s of 16 nM and 1.03 μM, respectively. ALK/HDAC-IN-1 exhibits antitumor activity[1]. |
| Invitro | ALK/HDAC-IN-1 抑制癌细胞 A549，HepG2，MCF7，U87MG 和 H2228 增殖，IC50 分别为 0.33，0.59，0.55，0.62 和 0.44 μM[1]。ALK/HDAC-IN-1 抑制 CYP450 酶 CYP2C9，IC50 为 2.65 μM[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> ALK/HDAC-IN-1 相关抗体: Cell Proliferation Assay[1] Cell Line: |
| In Vivo | ALK/HDAC-IN-1 (0-20 mg/kg，腹腔注射 21 天) 抑制 A549 异种移植 BALB/c 小鼠的肿瘤生长，无明显毒性[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| Formula | C27H31N5O4 |
| Molar Mass | 489.57 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Wang KL, et al., Discovery of novel anaplastic lymphoma kinase (ALK) and histone deacetylase (HDAC) dual inhibitors exhibiting antiproliferative activity against non-small cell lung cancer. J Enzyme Inhib Med Chem. 2024 Dec;39(1):2318645. |